Yanjun Zhu

No.180 Fenglin Road
Zhongshan, 200032, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 41 publications

TFPI2 expression predicts resistance to immunotherapy plus tyrosine kinase inhibitor and informs first-line therapy selection in metastatic renal cell carcinoma.

TFPI2 expression predicts resistance to immunotherapy plus tyrosine kinase inhibitor and informs first-line therapy selection in metastatic renal cell carcinoma.

Journal: Cellular oncology (Dordrecht, Netherlands)

Published: October 21, 2025

The CT-based deep learning model outperforms traditional anatomical classification models in preoperatively predicting complications and risk grade in partial nephrectomy.

The CT-based deep learning model outperforms traditional anatomical classification models in preoperatively predicting complications and risk grade in partial nephrectomy.

Journal: World journal of urology

Published: June 12, 2025

KPNA2 expression as a biomarker for immunosuppressive microenvironment predicting response to TKI and immunotherapy in metastatic renal cell carcinoma.

KPNA2 expression as a biomarker for immunosuppressive microenvironment predicting response to TKI and immunotherapy in metastatic renal cell carcinoma.

Journal: European journal of pharmacology

Published: April 13, 2025

Thymidine kinase 1 indicates resistance to immune checkpoint plus tyrosine kinase inhibition in renal cell carcinoma.

Thymidine kinase 1 indicates resistance to immune checkpoint plus tyrosine kinase inhibition in renal cell carcinoma.

Journal: Cellular oncology (Dordrecht, Netherlands)

Published: February 12, 2025

Integrated analysis of single-cell and bulk transcriptomes uncovers clinically relevant molecular subtypes in human prostate cancer.

Integrated analysis of single-cell and bulk transcriptomes uncovers clinically relevant molecular subtypes in human prostate cancer.

Journal: Chinese journal of cancer research = Chung-kuo yen cheng yen chiu

Published: September 28, 2024

PSMD2 overexpression as a biomarker for resistance and prognosis in renal cell carcinoma treated with immune checkpoint and tyrosine kinase inhibitors.

PSMD2 overexpression as a biomarker for resistance and prognosis in renal cell carcinoma treated with immune checkpoint and tyrosine kinase inhibitors.

Journal: Cellular oncology (Dordrecht, Netherlands)

Published: July 23, 2024

SPP1 expression indicates outcome of immunotherapy plus tyrosine kinase inhibition in advanced renal cell carcinoma.

SPP1 expression indicates outcome of immunotherapy plus tyrosine kinase inhibition in advanced renal cell carcinoma.

Journal: Human vaccines & immunotherapeutics

Published: May 13, 2024

Effect of Annexin A2 on prognosis and sensitivity to immune checkpoint plus tyrosine kinase inhibition in metastatic renal cell carcinoma.

Effect of Annexin A2 on prognosis and sensitivity to immune checkpoint plus tyrosine kinase inhibition in metastatic renal cell carcinoma.

Journal: Discover oncology

Published: September 05, 2023

Renal anatomical classification systems cannot predict the occurrence of vascular complications after partial nephrectomy.

Renal anatomical classification systems cannot predict the occurrence of vascular complications after partial nephrectomy.

Journal: World journal of urology

Published: July 16, 2023

Clinical Significance of Preoperative Assessment of Intravesical Prostatic Protrusion in Radical Prostatectomy.

Clinical Significance of Preoperative Assessment of Intravesical Prostatic Protrusion in Radical Prostatectomy.

Journal: Journal of Cancer

Published: May 28, 2023

Effect of galectin-1 on prognosis and responsiveness of immune checkpoint plus tyrosine kinase inhibition in renal cell carcinoma.

Effect of galectin-1 on prognosis and responsiveness of immune checkpoint plus tyrosine kinase inhibition in renal cell carcinoma.

Journal: Cancer medicine

Published: March 30, 2023

RUNX3 pathway signature predicts clinical benefits of immune checkpoint inhibition plus tyrosine kinase inhibition in advanced renal cell carcinoma.

RUNX3 pathway signature predicts clinical benefits of immune checkpoint inhibition plus tyrosine kinase inhibition in advanced renal cell carcinoma.

Journal: BMC urology

Published: March 28, 2023

Showing 1-12 of 41

Last Updated: 09/26/2026